| Document Date: 2015-05-08 12:54:04
Open Document File Size: 315,76 KBShare Result on Facebook
Company Canaan Partners / 5AM Ventures / Spyryx Biosciences Inc. / Spyryx Biosciences Spyryx Biosciences / Hatteras Venture Partners / / Currency USD / / Event Employment Change / Funding / Business Partnership / / Facility University of North Carolina / laboratory of Dr. Robert Tarran / / IndustryTerm venture capital financing / privatelyheld biopharmaceutical company developing novel therapeutics / Therapeutics for Respiratory Diseases / therapies for devastating pulmonary diseases / / MedicalCondition genetic disease / COPD / disease / obstructive lung diseases / chronic bacterial colonization / diseases / chronic obstructive pulmonary disorder / pulmonary drug development / pulmonary diseases / cystic fibrosis / pulmonary symptoms / Respiratory Diseases / progressive dehydration / / Organization National Institute of Health / University of North Carolina / North Carolina Biotechnology Center / / Person John Taylor / Tim Shannon / Chapel Hill / Robert Tarran / Christy Shaffer / Don Rose / Brian Daniels / Carolina KickStart / / Position board member / general partner / Chairman / President and CEO / managing director / / ProvinceOrState North Carolina / / Technology Biotechnology / drug development / / URL www.spyryxbio.com / /
SocialTag |
Spyryx Biosciences Secures $18 Million in Series A Financing Funding to Develop Novel Therapeutics for Respiratory Diseases Venture Syndicate has Strong Respiratory Expertise